TNFi and csDMARD co-medication | TNFi monotherapy | |||
Proportion missing data | Proportion missing data | |||
N (%) | 9440 (62%) | 5892 (38%) | ||
Age, years, mean (SD) | 48.9 (12.1) | 0% | 49.0 (12.6) | 0% |
Sex (male), % | 50% | 0% | 48% | 0% |
Disease duration, years mean (SD) | 6.3 (7.1) | 28% | 6.2 (7.3) | 32% |
CRP, mg/L, mean (SD) | 13.6 (21.3) | 18% | 9.1 (16.9) | 25% |
Tender joints 28, mean (SD) | 6.2 (5.9) | 21% | 5.6 (6.1) | 32% |
Swollen joints 28, mean (SD) | 3.9 (4.2) | 21% | 2.9 (4.0) | 32% |
VAS global health, mm, mean (SD) | 59.2 (24.0) | 21% | 58.1 (25.6) | 28% |
VAS pain, mm, mean (SD) | 57.4 (23.6) | 30% | 56.3 (25.7) | 34% |
DAPSA28, mean (SD) | 28.8 (16.0) | 38% | 26.0 (16.9) | 46% |
DAS28-CRP, mean (SD) | 4.2 (1.2) | 29% | 3.8 (1.3) | 41% |
Type of TNFi | ||||
Adalimumab, % | 32% | – | 33% | – |
Certolizumab pegol, % | 6% | – | 4% | – |
Etanercept, % | 30% | – | 40% | – |
Golimumab, % | 11% | – | 10% | – |
Infliximab, % | 20% | – | 13% | – |
Type of csDMARD used as co-medication | ||||
Methotrexate, % | 79% | – | – | – |
Sulfasalazine, % | 15% | – | – | – |
Leflunomide, % | 11% | – | – | – |
Other*, % | 6% | – | – | – |
*See the list of all csDMARDs in Methods section.
CRP, C reactive protein; csDMARD, conventional synthetic disease modifying anti-rheumatic drugs; DAPSA28, disease activity index for psoriatic arthritis with 28 joints; DAS28-CRP, disease activity score with 28 joints and CRP; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitors; VAS, visual analogue scale.